ezetimibe has been researched along with Xanthoma in 14 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (28.57) | 29.6817 |
| 2010's | 6 (42.86) | 24.3611 |
| 2020's | 4 (28.57) | 2.80 |
| Authors | Studies |
|---|---|
| Choi, SH; Jeong, IK; Kang, HJ; Kim, BJ; Lee, CJ; Lee, SH; Yoon, M | 1 |
| Lin, Z; Yang, C; Zhong, Z | 1 |
| Hirano, S; Kawashiri, MA; Nomura, A; Tada, H; Takenaga, M; Tanaka, H; Watanabe, Y | 1 |
| Arai, H; Bujo, H; Daida, H; Harada-Shiba, M; Ishibashi, S; Koga, N; Masuda, D; Oikawa, S; Yamashita, S | 1 |
| Bastida, JM; Benito, R; Díez-Campelo, M; Girós, M; González-Porras, JR; Hernández-Rivas, JM; Hernández-Sánchez, JM; Hortal, A; Janusz, K; Lozano, ML; Marcellini, S; Rivera, J | 1 |
| Jones, PJ; Myrie, SB; Othman, RA | 1 |
| Blanco-Vaca, F; Cedó, L; Escolà-Gil, JC; Julve, J; Martín-Campos, JM; Quesada, H | 1 |
| Levesque, MC; Liang, KP; Mock, GD; Modi, SR; Ruiz, XD | 1 |
| Bulai Livideanu, C; Ferrières, J; Lamant, L; Maybon, P; Mazereeuw-Hautier, J; Paul, C; Periquet, B; Royer, M | 1 |
| Al-Sarraf, A; Frohlich, J; Li, M; Mattman, A | 1 |
| Al-Abri, A; Al-Dhuhli, H; Al-Hashmi, K; Al-Hinai, AT; Al-Rasadi, K; Al-Sabti, H; Al-Waili, K; Al-Yaarubi, S; Al-Zakwani, I; Banerjee, Y | 1 |
| Angelin, B; Eggertsen, G; Eriksson, M; Lind, S; Olsson, AG; Rudling, M | 1 |
| Patel, SB; Salen, G; Sisk, CM; Starc, T | 1 |
| Conejo-Mir, JS; Fernandez-Freire, LR; Guirado, SS; Muñoz, MA; Ortíz, JV; Wite, JB | 1 |
4 review(s) available for ezetimibe and Xanthoma
| Article | Year |
|---|---|
2022 Consensus statement on the management of familial hypercholesterolemia in Korea.
Topics: Adult; Child; Cholesterol, LDL; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type II; Proprotein Convertase 9; Xanthomatosis | 2022 |
Two novel variants of the ABCG5 gene cause xanthelasmas and macrothrombocytopenia: a brief review of hematologic abnormalities of sitosterolemia.
Topics: Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; DNA Mutational Analysis; Ezetimibe; Female; Genetic Predisposition to Disease; High-Throughput Nucleotide Sequencing; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Lipoproteins; Middle Aged; Mutation; Phenotype; Phytosterols; Sitosterols; Spain; Thrombocytopenia; Xanthomatosis | 2017 |
Non-cholesterol sterols and cholesterol metabolism in sitosterolemia.
Topics: Absorption; Atherosclerosis; ATP Binding Cassette Transporter, Subfamily G; ATP-Binding Cassette Transporters; Azetidines; Cholesterol; Disease Progression; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Kinetics; Lipid Metabolism, Inborn Errors; Membrane Proteins; Membrane Transport Proteins; Phytosterols; Sitosterols; Sterol O-Acyltransferase; Sterol O-Acyltransferase 2; Sterols; Xanthomatosis | 2013 |
Sitosterolemia: diagnosis, investigation, and management.
Topics: Anemia, Hemolytic; Animals; Anticholesteremic Agents; Atherosclerosis; Azetidines; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Mice; Phytosterols; Thrombocytopenia; Xanthomatosis | 2014 |
10 other study(ies) available for ezetimibe and Xanthoma
| Article | Year |
|---|---|
Sitosterolaemia presenting with consistent skin xanthomas in a pair of monozygotic twins who responded to ezetimibe treatment.
Topics: Ezetimibe; Humans; Hypercholesterolemia; Twins, Monozygotic; Xanthomatosis | 2023 |
Sitosterolemia Exhibiting Severe Hypercholesterolemia with Tendon Xanthomas Due to Compound Heterozygous ABCG5 Gene Mutations Treated with Ezetimibe and Alirocumab.
Topics: Achilles Tendon; Antibodies, Monoclonal, Humanized; Anticholesteremic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 5; Cholesterol, LDL; Ezetimibe; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Male; Middle Aged; Mutation; Phytosterols; Treatment Outcome; Xanthomatosis | 2020 |
Effectiveness and Safety of Lipid-Lowering Drug Treatments in Japanese Patients with Familial Hypercholesterolemia: Familial Hypercholesterolemia Expert Forum (FAME) Study.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol; Cholesterol, LDL; Ezetimibe; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Japan; Male; Probucol; Xanthomatosis | 2022 |
20-year-old amish woman with abdominal pain, retroperitoneal mass, and hyperlipidemia.
Topics: Abdominal Pain; Amish; Anticholesteremic Agents; Azetidines; Biopsy; Diagnosis, Differential; Ezetimibe; Female; Humans; Hypercholesterolemia; Intestinal Diseases; Lipid Metabolism, Inborn Errors; Phytosterols; Predictive Value of Tests; Retroperitoneal Fibrosis; Retroperitoneal Space; Tomography, X-Ray Computed; Treatment Outcome; Xanthomatosis; Young Adult | 2015 |
[Orange skin and xanthomas associated with lycopenaemia in a setting of type III dyslipoproteinemia].
Topics: Azetidines; Carotenoids; Ezetimibe; Female; Humans; Hyperlipoproteinemia Type III; Hypolipidemic Agents; Lycopene; Middle Aged; Niacin; Pigmentation Disorders; Skin Diseases; Xanthomatosis | 2009 |
Use of once-weekly statin in combination with ezetimibe in a patient with mitochondrial disease.
Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Female; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Mitochondrial Diseases; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Xanthomatosis | 2012 |
First case report of familial hypercholesterolemia in an Omani family due to novel mutation in the low-density lipoprotein receptor gene.
Topics: Achilles Tendon; Anticholesteremic Agents; Apolipoproteins B; Azetidines; Biomarkers; Blood Component Removal; Carotid Artery Diseases; Carotid Intima-Media Thickness; Child; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; DNA Mutational Analysis; Drug Combinations; Exons; Eye Diseases; Ezetimibe; Female; Fluorobenzenes; Frameshift Mutation; Genetic Predisposition to Disease; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Oman; Pedigree; Phenotype; Pyrimidines; Receptors, LDL; Rosuvastatin Calcium; Sequence Deletion; Sulfonamides; Treatment Outcome; Triglycerides; Xanthomatosis | 2013 |
Autosomal recessive hypercholesterolaemia: normalization of plasma LDL cholesterol by ezetimibe in combination with statin treatment.
Topics: Adult; Anticholesteremic Agents; Azetidines; Child; Cholesterol, LDL; Drug Combinations; Ezetimibe; Fluorobenzenes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipoproteinemia Type II; Male; Pedigree; Pyrimidines; Rosuvastatin Calcium; Sulfonamides; Xanthomatosis | 2004 |
Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis.
Topics: Anticholesteremic Agents; Azetidines; Child; Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Ezetimibe; Female; Follow-Up Studies; Humans; Risk Assessment; Severity of Illness Index; Sitosterols; Treatment Outcome; Xanthomatosis | 2006 |
Sitosterol xanthomatosis.
Topics: Azetidines; Ezetimibe; Female; Humans; Hypolipidemic Agents; Middle Aged; Sitosterols; Xanthomatosis | 2007 |